Home Industry Reports Custom Research Blogs About Us Contact us

U.S. Biguanides Market

Report ID: FBI 4099

|

Published Date: Jun-2024

|

Format : PDF, Excel

Market Outlook:

The U.S. biguanides market is poised for significant growth over the forecast period, driven by the increasing prevalence of chronic diseases such as diabetes, obesity, and cardiovascular diseases. Biguanides are a class of drugs commonly used to treat type 2 diabetes and are also being explored for their potential in the treatment of other conditions such as polycystic ovary syndrome and cancer.

Biguanides Market

Largest Region

North America

38% Market Share in 2023

Get more details on this report -

Market Dynamics:

Growth Drivers:

1. Increasing prevalence of type 2 diabetes: The rising incidence of type 2 diabetes in the U.S. is a major driver for the biguanides market. Biguanides, such as metformin, are often the first-line treatment for type 2 diabetes due to their efficacy and relatively low side effect profile.

Report Coverage & Deliverables

Historical Statistics Growth Forecasts Latest Trends & Innovations Market Segmentation Regional Opportunities Competitive Landscape
2. Growing awareness of the benefits of biguanides: With increasing awareness among healthcare professionals and patients about the efficacy of biguanides in managing diabetes, the demand for these drugs is expected to rise in the coming years.

3. Expanding applications of biguanides: Biguanides are being studied for their potential in treating conditions beyond diabetes, such as polycystic ovary syndrome and cancer. This expanding applications of biguanides is expected to drive market growth.

Industry Restraints:

1. Side effects and safety concerns: While biguanides are generally considered safe and well-tolerated, they can cause gastrointestinal side effects such as diarrhea and nausea. These side effects can limit patient adherence to treatment and pose a challenge for market growth.

2. Competition from alternative therapies: The biguanides market faces competition from other classes of drugs for the treatment of diabetes, such as sulfonylureas and DPP-4 inhibitors. The availability of alternative therapies could impact the market share of biguanides.

Segment Analysis:

The U.S. biguanides market can be segmented based on product type, including metformin, buformin, and phenformin. Metformin is the most commonly prescribed biguanide and is expected to dominate the market throughout the forecast period due to its proven efficacy and safety profile.

Competitive Landscape:

Key players in the U.S. biguanides market include Bristol-Myers Squibb Company, Merck & Co. Inc., and Sanofi S.A. These companies are focused on research and development initiatives to expand the applications of biguanides and improve their formulations. Strategic collaborations and partnerships are also common among market players to strengthen their market presence and gain a competitive edge.

Our Clients

Why Choose Us

Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.

Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.

Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.

Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.

Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.

Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.

Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.

Select Licence Type

Single User

US$ 4250

Multi User

US$ 5050

Corporate User

US$ 6150

Biguanides Market Size & Share, By Drug Type (Bran...

RD Code : 24